Culture, arts & science

Crown Bioscience Achieves CAP 15189 Accreditation; ISO 15189 Standard for Quality Medical Laboratory Services

SAN DIEGO & HAMBURG, Germany & SUZHOU, China–(BUSINESS WIRE)– Crown Bioscience, a leading global contract research organization (CRO) and a JSR Life Sciences company, today...

Innovatieve Fat Z-Score biomarkers van AMRA Medical tonen aan dat de behandeling met tirzepatide geassocieerd is met een potentieel gericht effect op visceraal vet en levervet

Onderzoeksanalyse van de SURPASS-3 MRI-studie toont een significante vermindering van zowel viscerale als levervet z-scores, en een verschuiving naar een evenwichtiger vetverdelingspatroon met tirzepatidebehandeling LINKÖPING,...

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

– Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies – – Alpine’s lead product, povetacicept, demonstrated best-in-class potential...

AMRA Medical’s Innovative Fat Z-Score Biomarkers Show Tirzepatide Treatment is Associated with a Potential Targeted Effect on Visceral Fat and Liver Fat

Exploratory analysis from the SURPASS-3 MRI study shows significant reduction of both visceral- and liver fat z-scores, and a shift towards a more balanced fat...

Sanguine Biosciences bevestigt superieure kwaliteit van haar biospecimen-services aan de hand van VERIF.i®, het programma voor pre-assessment van leveranciers van Scientist.com

Fysieke labo-inspecties ter plaatse stellen providers van gereglementeerde biofarmaservices in staat om hun kwaliteit en capaciteiten aan prospectiepartners te demonstreren SAN DIEGO–(BUSINESS WIRE)– Scientist.com, de...

AACR 2024: Brenus Pharma Unveils Promising and Robust Pre-clinical Efficacy Extrapolating Human Conditions with STC-1010

LYON, France–(BUSINESS WIRE)– Brenus Pharma unveils groundbreaking results during the American Association Cancer Research (AACR) Annual meeting 2024 – San Diego (April 5-10). “Efficacy of...

Sanguine Biosciences Affirms Superior Quality of its Biospecimen Services Using VERIF.i®, Scientist.com’s Supplier Pre-assessment Program

Onsite, physical lab inspections enable providers of regulated biopharma services to showcase their quality and capabilities to prospective partners SAN DIEGO–(BUSINESS WIRE)– Scientist.com, the pharmaceutical...

Innovation Meets Regulation: internationale webinar ging op verkenning naar doeltreffende strategieën om roken tegen te gaan

LONDEN–(BUSINESS WIRE)– We Are Innovation hield de webinar “ Innovation Meets Regulation: The 2024 Effective Anti-Smoking Policies Global Index .” Dit krachtige overleg knoopte aan...

Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring

Ferring reported annual revenues of €2.2 billion, an increase of +1% at constant exchange rates, supported by robust sales performance in core franchise and legacy...

Innovation Meets Regulation: International Webinar Explored Effective Anti-Smoking Strategies

LONDON–(BUSINESS WIRE)– We Are Innovation hosted the webinar “Innovation Meets Regulation: The 2024 Effective Anti-Smoking Policies Global Index.” This powerful talk embarked on the official...

Vergelijkende studie fase 3 van Prolia ® en Xgeva ® (denosumab) biosimilaire kandidaat HLX14 beantwoordde aan de primaire eindpunten

SHANGHAI, China & JERSEY CITY, N.J.–(BUSINESS WIRE)– Shanghai Henlius Biotech, Inc. (2696.HK) en Organon (NYSE: OGN) kondigden aan dat de vergelijkende studie van fase 3...

Delta-Fly Pharma Inc.: kennisgeving van toestemming voor uitvoering van de Fase I/II-studie van DFP-10917 in combinatie met Venetoclax

TOKUSHIMA, Japan–(BUSINESS WIRE)– In navolging van de eerdere informatie op 11 maart 2024 zijn we verheugd om onze nieuwste ontwikkelingsstatus te delen. Met genoegen kondigen...

Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 combined with Venetoclax

TOKUSHIMA, Japan–(BUSINESS WIRE)– Following to the previous information on March 11th, 2024, we are excited to share our latest development status. We are pleased to...

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

SHANGHAI, China & JERSEY CITY, N.J.–(BUSINESS WIRE)– Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for...

Quanta System opnieuw aan de top van de urologische laserwereld met Quanta Magneto Technology™

PARIJS–(BUSINESS WIRE)– Ter gelegenheid van het 39e European Association of Urology Congress EAU profileert Quanta System zich als een laserfabrikant van wereldklasse aan de zijde...